Skip to main content

Table 1 Patients with P. vivax or mixed ( P. vivax and P. falciparum ) malaria treated at IPEC (2005-2011), classified according to therapeutic response

From: Plasmodium vivax malaria relapses at a travel medicine centre in Rio de Janeiro, a non-endemic area in Brazil

 

Non-Relapse

Relapse

Median [CI 95%] (days)

p (Log-Rank)

 

n

%

N

%

  

Sample

32

100

21

100

108 [69-NA}

 

Gender

      

Men

22

68.8

18

85.7

104 [68-NA]

0.16

Women

10

31.2

3

14.3

NA [58-NA]

 

Age range (years)

      

14-30

14

43.8

14

66.7

79 [58-NA]

0.22

31-50

13

40.6

4

19.0

369 [108-NA]

 

≥51

5

15.6

3

14.3

68 [51-NA]

 

Adverse drugs events (ADE)*

      

Yes

10

31.3

2

9.5

NA [58-NA]

0.20

No

17

53.1

12

57.1

108 [68-NA]

 

Duration of primaquine therapy*

      

Short regimen

19

59.4

16

76.2

79 [65-NA]

0.34

Long regimen

10

31.3

4

19.0

218 [104-NA]

 

Primaquine total dose adjusted by weight*

      

Yes (≥ 3.2 mg/kg)

25

78.1

12

57.1

182 [104-NA]

0.03

No (< 3.2 mg/kg)

5

15.6

6

28.3

54 [40-NA]

 
  1. * Missing data was 22.6%, 7.5% and 9.4% for ADE, duration of treatment with primaquine and primaquine dose adjusted by weight, respectively.
  2. NA = not achieved.